Atopic dermatitis and the atopic march: Considering racial and ethnic diversity in atopic disease progression - 04/05/22
Doi : 10.1016/j.jaci.2022.03.008
Junko Takeshita, MD, PhD, MSCE a, b, Jayanta Gupta, MD, PhD c, Yaqian Zhu, MS b, Ronald Berna, BA a, Zelma C. Chiesa Fuxench, MD, MSCE a, b, David J. Margolis, MD, PhD a, b, ⁎ 
a Department of Dermatology, Perelman School of Medicine, Philadelphia, Pa
b Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Philadelphia, Pa
c Department of Health Sciences, Marieb College of Health and Human Services, Florida Gulf Coast University, Fort Meyers, Fla
∗Corresponding author: David J. Margolis, MD, PhD, University of Pennsylvania, Dermatology and Epidemiology, 901 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104.University of PennsylvaniaDermatology and Epidemiology901 Blockley Hall, 423 Guardian DrivePhiladelphiaPA19104
Key words : Atopic dermatitis, atopic march, asthma, seasonal allergy
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: J. Takeshita receives a research grant (to the Trustees of the University of Pennsylvania) from Pfizer, Inc, and has served as a consultant for Pfizer, Inc, and Janssen Biotech, receiving honoraria. Z. C. Chiesa Fuxench has served as a consultant for the Asthma and Allergy Foundation of America, the National Eczema Association, AbbVie, Beiersdorf, Incyte Corporation, and Pfizer; received research grants from Eli Lilly, LEO Pharma, Regeneron, Sanofi, Tioga, and Vanda for work related to atopic dermatitis and from Menlo Therapeutics for work related to prurigo nodularis; and received honoraria for continuing medical education work in atopic dermatitis sponsored by education grants from Regeneron/Sanofi and Pfizer. D. J. Margolis has consulting relationships with the National Eczema Association, Pfizer, Janssen Pharmaceuticals, and Insmed, and he receives research funding from the National Institutes of Health, Pfizer, and Bausch Health; all of the aforementioned funds are paid to the Trustees of the University of Pennsylvania. The rest of the authors declare that they have no relevant conflicts of interest. None of the relationships or funders mentioned were involved in development of this article. |
© 2022
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 5
P. 1590-1591 - mai 2022 Retour au numéro
Article précédent
- Fevipiprant in CRSwNP and comorbid asthma: Wrong target population or wrong PGD2 receptor?
- Katherine N. Cahill
- Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH)
- Deepak Kumar, Christina A. Rostad, Preeti Jaggi, D. Sofia Villacis Nunez, Chengyu Prince, Austin Lu, Laila Hussaini, Thinh H. Nguyen, Sakshi Malik, Lori A. Ponder, Sreekala P.V. Shenoy, Evan J. Anderson, Michael Briones, Ignacio Sanz, Sampath Prahalad, Shanmuganathan Chandrakasan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?